China's Everest Medicines climbs as US FDA approves Nefecon capsules

Calliditas Therapeutics AB

21/12/2023 06:59

** Shares of Everest Medicines  1952.HK  up ~3.8% at
HK$19.36 in second session of gains
    ** Shanghai-based co's licensing partner Calliditas
Therapeutics  CALTX.ST  announced that U.S. FDA had approved
Nefecon capsules for adult patients
    ** Capsule is used to treat immunoglobulin A nephropathy to
slow decline in kidney function
    ** Hong Kong's healthcare index  .HSCIH  falls 1.3%, while
Hang Seng Index  .HSI  edges up 0.02%
    ** Stock up 11.4% YTD

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))